Ospemifene

Ospemifene (brand names Osphena and Senshio produced by Shionogi) is an oral medication indicated for the treatment of dyspareunia – pain during sexual intercourse – encountered by some women, more often in those who are post-menopausal. Ospemifene is a selective estrogen receptor modulator (SERM) acting similarly to an estrogen on the vaginal epithelium, building vaginal wall thickness which in turn reduces the pain associated with dyspareunia. Dyspareunia is most commonly caused by "vulvar and vaginal atrophy."

Ospemifene
Clinical data
Trade namesOsphena, Senshio
Other namesDeaminohydroxytoremifene
License data
Routes of
administration		By mouth
Drug classSelective estrogen receptor modulator
ATC code
Legal status
Legal status
Identifiers
  • 2-(p-((Z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
ECHA InfoCard100.190.672
Chemical and physical data
FormulaC24H23ClO2
Molar mass378.90 g·mol−1
3D model (JSmol)
  • OCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1
  • InChI=1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2/b24-23-
  • Key:LUMKNAVTFCDUIE-VHXPQNKSSA-N

The medication was approved by the FDA in February 2013 and by the European Commission for marketing in the EU in January 2015.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.